3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Transitional Cell
16
Urinary Bladder Neoplasms
15
Carcinoma, Merkel Cell
10
Neoplasm Metastasis
8
Carcinoma, Renal Cell
8
Breast Neoplasms
8
Neoplasms
6
Triple Negative Breast Neoplasms
5
Melanoma
5
Ureteral Neoplasms
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Urethral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Neuroendocrine Tumors
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Urothelial Cancer
1
Turcot syndrome
1
Thymoma
1
Interventions
pembrolizumab
3
Paclitaxel
3
Doxorubicin
3
durvalumab
2
Standard of Care
2
Nivolumab
2
Ipilimumab
2
Ifosfamide
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
peginterferon alfa-2a
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
eribulin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
avelumab
×
1 year
×
Clear all
No trials found.